

Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases. Among its major competitors, Pulmatrix is ranked in 10th place for NPS while Biogen is 1st, and Theravance Biopharma is 2nd.Their current market cap is $10.15M